Calcium Gluconate

證據等級: L5

預測適應症: 0 個

Calcium Gluconate: No Repurposing Predictions Available

One-Sentence Summary

Calcium gluconate is a well-established calcium salt compound used clinically for electrolyte management and conditions such as hypocalcemia. The TxGNN model did not generate any new indication predictions for this compound in the current analysis run. Without predicted indications, a formal repurposing pathway evaluation cannot be completed at this stage; a Hold decision is recommended pending data remediation.

Quick Overview

Item	Content
Original Indication	No formal indication data recorded in this Evidence Pack
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	N/A
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Philippines Market Information

There are currently no Philippine FDA registrations on record for Calcium gluconate (DrugBank: DB11126) in this Evidence Pack. The drug is classified as not marketed in the Philippines.

No license entries are available to tabulate.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model returned an empty prediction list for Calcium gluconate, and all critical evaluation inputs — original indication, mechanism of action, safety warnings, and contraindication data — are absent or unconfirmed. There is no evidence base upon which to build a repurposing case at this time.

To proceed, the following is needed:

Investigate the empty prediction output — confirm that the DrugBank ID DB11126 is correctly mapped in the knowledge graph (node.csv / kg.csv) and that the drug node has sufficient edges to generate predictions; if the node is isolated or absent, re-run the KG pipeline after patching the mapping.
Obtain mechanism of action (MOA) data — query the DrugBank API for DB11126 to populate the pharmacological class and target information needed for mechanistic rationale analysis.
Obtain safety profile — download the Philippine FDA (or reference-country) package insert PDF and parse warnings, contraindications, and drug interaction sections to clear data gaps DG001 and DG002.
Confirm original indication(s) — the original_indications array is empty; populate from the DrugBank “Indication” field or authoritative label to enable the standard indication-to-new-indication comparison.
Re-run TxGNN prediction pipeline — once data gaps are remediated, re-execute the KG and deep-learning prediction steps and regenerate the Evidence Pack (target version: v5).
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.